Global and United States Primary Biliary Cirrhosis Drug In-Depth Research Report 2017-2022

SKU ID : USMI- 10820475

Publishing Date : 22-Dec-2017

No. of pages : 102

PRICE
3190
6380


  • The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.

    This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Primary Biliary Cirrhosis Drug industry.

    Major Companies
    AlbireoPharma
    CymaBay Therapeutics, Inc.
    Dr. Falk Pharma GmbH
    Enanta Pharmaceuticals, Inc.
    GlaxoSmithKline Plc
    Intercept Pharmaceuticals, Inc.
    Johnson & Johnson
    MediGene AG
    NGM Biopharmaceuticals, Inc.
    Virobay Inc.

    Key Regions
    North America
    United States
    California
    Texas
    New York
    Others
    Canada
    Latin America
    Mexico
    Brazil
    Argentina
    Others
    Europe
    Germany
    United Kingdom
    France
    Italy
    Spain
    Russia
    Netherland
    Others
    Asia & Pacific
    China
    Japan
    India
    Korea
    Australia
    Southeast Asia
    Indonesia
    Thailand
    Philippines
    Vietnam
    Singapore
    Malaysia
    Others
    Africa & Middle East
    South Africa
    Egypt
    Turkey
    Saudi Arabia
    Iran
    Others

    Main types of products
    Primary Biliary Cirrhosis Drug Market, bydesonide
    Primary Biliary Cirrhosis Drug Market, byP-104
    Primary Biliary Cirrhosis Drug Market, byK-2330672
    Primary Biliary Cirrhosis Drug Market, byX-8025
    Primary Biliary Cirrhosis Drug Market, byM-282

    Primary Biliary Cirrhosis Drug Market, by Key Consumers
    Clinic
    Hospital
    Others